Illumina Takes a Hit as Beijing Retaliates Against U.S. Tariffs
China announced on Tuesday a ban on imports of genetic sequencers from U.S. medical equipment maker Illumina (ILMN), marking its latest response to escalating trade tensions with the United States. The decision came just minutes after the U.S. imposed an additional 10% tariff on Chinese goods, further intensifying the economic standoff between the two nations.
Illumina’s stock tumbled more than 4% in premarket trading following the announcement, with shares sliding 2.8% to $81.81. The ban, which takes effect on March 4, follows Beijing’s decision in February to place Illumina on its “unreliable entity” list, citing the company’s alleged discriminatory practices against Chinese enterprises.
Impact on Illumina and the Global Gene Sequencing Market
China accounts for approximately 7% of Illumina’s total sales, making this ban a notable blow to the company’s revenue. Genetic sequencers play a crucial role in medical research and diagnostics, allowing scientists to analyze DNA and RNA sequences to study genetic variations and detect rare diseases.
Illumina responded to the ban by stating that it remains committed to serving customers in China while ensuring compliance with the latest regulations set by Beijing’s Ministry of Commerce. The company is currently assessing the full impact of the ban on its operations in China.
However, Illumina has already been facing challenges in the Chinese market due to increasing competition from domestic firms such as BGI Genomics and MGI Tech. The company’s sales in Greater China declined nearly 20% last year to $308 million, highlighting the difficulties of operating in an increasingly protectionist environment.
Winners and Losers in China’s Retaliation
While Illumina faces setbacks, its Chinese rivals have surged ahead. Shares in BGI Genomics jumped 8.4% on Tuesday, while MGI Tech’s stock soared by the daily limit of 20%, as investors anticipate these companies capturing market share previously held by Illumina.
Nomura analysts estimate that the ban could generate a $103 million business opportunity for MGI Tech in 2025 alone. The decision also aligns with China’s broader strategy of reducing dependence on U.S. technology amid ongoing trade conflicts.
Escalating Trade Disputes and Future Implications
The Illumina ban is the latest in a series of retaliatory measures by China against U.S. businesses. In February, Beijing placed PVH Corp—the parent company of Calvin Klein and Tommy Hilfiger—on its unreliable entity list and launched an investigation into Google. Companies on this list face potential fines, trade restrictions, and revocation of work permits for foreign staff.
China’s move against Illumina also follows U.S. efforts to restrict business with Chinese biotech firms like MGI and BGI over alleged national security concerns. Both Chinese firms have denied the allegations, but the intensifying dispute underscores the growing divide between the world’s two largest economies.
As the trade war continues to escalate, U.S. companies operating in China may face increasing challenges, while Chinese firms are likely to benefit from protectionist policies that favor domestic players.
You might like this article:FDA Closes Inspection of BioXcel’s TRANQUILITY II Trial Site, Reinforcing Data Integrity
